乌帕替尼与阿布昔替尼治疗中重度特应性皮炎的效果对比OA

Objective:To compare the clinical efficacy of Upadacitinib and Abrocitinib in the treatment of moderate-to-severe atopic dermatitis,and to analyze the effects of the two drugs on severity of illness,pruritus symptoms,symptoms sleep quality and quality of life of patients.Method:A total of 91 patients with moderate-to-severe atopic dermatitis admitted to the Department of Dermatology,Xinyi People's Hospital from April 2023 to November 2025 were enrolled and divided into group A(46 cases,conventional treatment+Abrocitinib)and group B(45 cases,conventional treatment+Upadacitinib)by random number table method.All patients received continuous treatment for 16 weeks.The scores of eczema area and severity index(EASI),investigator's global assessment(IGA),severity of pruritus(VAS),Pittsburgh sleep quality index(PSQI)and dermatology life quality index(DLQI)were evaluated before treatment and after 4,8 and 16 weeks of treatment,and adverse reactions were recorded.Result:After 4,8 and 16 weeks of treatment,the scores of EASI,IGA,VAS,PSQI and DLQI in group B were lower than those in group A(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Upadacitinib is superior to Abrocitinib in improving skin lesions,pruritus,sleep and quality of life in the treatment of moderate-to-severe atopic dermatitis.